Risk of progression within 24 months | Risk of death within 5 years | ||||||
---|---|---|---|---|---|---|---|
Univariable | Multivariable | Univariable | Multivariable | ||||
n(events) | HR(95%CI) | HR(95%CI) | n(events) | HR(95%CI) | HR(95%CI) | ||
Age | |||||||
Continuous | 134(19) | 1.02(0.98-1.07) | 1.01(0.97-1.06) | 231(88) | 1.06(1.04-1.09) | 1.06(1.04-1.08) | |
Gender | |||||||
Female | 29(2) | 1.00 | 1.00 | 43(12) | 1.00 | 1.00 | |
Male | 105(17) | 2.48(0.57-10.74) | 1.98(0.45-8.64) | 188(76) | 0.62(0.34-1.13) | 1.67(0.90-3.10) | |
Grade | |||||||
Low | 48(3) | 1.00 | 1.00 | 81(19) | 1.00 | 1.00 | |
High | 86(16) | 3.24(0.94-11.12) | 3.32(0.97-11.40) | 150(69) | 2.22(1.33-3.68) | 1.31(0.73-2.35) | |
Stage | |||||||
Ta | 68(7) | 1.00 | 1.00 | 115(35) | 1.00 | 1.00 | |
T1 | 66(12) | 1.90(0.75-4.83) | 1.24(0.44-3.46) | 116(53) | 0.61(0.40-0.93) | 1.61(1.04-2.49) | |
RBM3 expression* | RBM3 expression* | ||||||
High | 31(1) | 1.00 | 1.00 | Positive | 198(69) | 1.00 | 1.00 |
Negative/Intermediate | 103(18) | 5.92(0.79-44.39) | 6.10(0.81-45.69) | Negative | 33(19) | 2.00(1.21-3.33) | 1.64(0.96-2.78) |